The WTX, Wilms tumor-associated tumor-suppressor gene, is present on the X chromosome and a single WTX mutation may be sufficient to promote carcinogenesis. Unlike the WT1 tumor suppressor, a transcription factor, WTX lacks conserved functional protein domains. To study the function of WTX, we constructed inducible cell lines expressing WTX and tumor-associated WTX mutants. Induction of WTX inhibited cell growth and caused G 1 /G 0 arrest. In contrast, a short, tumorassociated truncation mutant of WTX358 only slightly inhibited cell growth without a significant cell-cycle arrest, although expression of a longer truncation mutant WTX565 led to the growth inhibition and cell-cycle arrest to a similar extent as wild-type WTX. Like WT1, WTX slowed growth and caused cell-cycle arrest through p21 induction. Gene expression profiling showed that these two tumorsuppressors regulated genes in similar pathways, including those implicated in control of the cellular growth, cell cycle, cell death, cancer and cardiovascular system development. When gene expression changes mediated by wild-type WTX were compared with those affected by mutant forms, WTX565 showed a 55% overlap (228 genes) in differentially regulated genes, whereas WTX358 regulated only two genes affected by wild-type WTX, implying that amino-acid residues 358-561 are critical for WTX function.
Introduction
Wilms tumor results from the malignant transformation of residual undifferentiated fetal kidney cells, yielding tumors with a triphasic histopathology of blastemal, stromal and epithelial components (reviewed in Rivera and Haber, 2005) . The genetic etiology of Wilms tumor is heterogeneous and incompletely understood. Wilms tumors may occur in sporadic forms or as a hereditofamilial form associated with in-utero mutation of the WT1 gene and subsequent loss or mutation of the remaining normal WT1 allele. Sporadic Wilms tumors may be associated with bi-allelic mutation of WT1 in up to 15% of cases (reviewed in (Huff, 1998) ). Loss of WT1 is frequently accompanied by gain of function mutations of CTNNB1 (Koesters et al., 1999; Maiti et al., 2000; Li et al., 2004) . Sporadic Wilms tumors without WT1 mutation frequently show loss of imprinting of IGF2 locus and many genes within this region may be deregulated (Ogawa et al., 1993) . Wilms tumors are also associated with loss of imprinting of the IGF2 region in the Beckwith-Wiedemann syndrome (Ohlsson et al., 1993; Weksberg et al., 1993) . Wilms tumors are generally sensitive to chemotherapy. Accordingly, p53 mutations are found infrequently in these tumors, and are associated with an anaplastic and highly aggressive phenotype (Bardeesy et al., 1995) . Recently, array comparative genomic hybridization in Wilms tumors reveals a discrete loss of genetic region on the X chromosome encompassing the WTX locus. In that initial report, WTX mutations or deletions are found in 30% of Wilms tumors (Rivera et al., 2007) . Without a homologue on the Y chromosome and subjected to X inactivation, WTX is a single copy tumor suppressor; hence loss or mutation of a single allele appears to be sufficient to allow tumor formation. Analysis of a small panel of Wilms tumors initially suggests that WT1 and WTX mutations are mutually exclusive, while later studies with a larger sets of tumors shows that WTX mutations (7-18% of cases) occurs at a similar frequency as WT1 mutations and WT1 and WTX mutations can be found in the same tumor (Perotti et al., 2008; Ruteshouser et al., 2008; Wegert et al., 2009) . WTX mutations are rare in other tumor types (Chung et al., 2008; Owen et al., 2008; Yoo et al., 2009) . Furthermore, microdissection of Wilms tumors shows that WTX mutations are not found uniformly within a tumor (Wegert et al., 2009) . This suggests that WTX inactivation is not an early causal event to drive tumorigenesis, but rather a late event, possibly involved in tumor progression. Germline mutations in WT1 predispose children to Wilms tumors as well as genitourinary malformations. In contrast, germline truncation mutations of WTX are not associated with an increased incidence of tumors but instead may cause increased bone density and craniofacial malformations in females and lethality in males (Jenkins et al., 2009 ).
Given the clear importance of Wnt signaling in kidney development and the presence of WTX mutations in a substantial fraction of Wilms tumors, it is significant to find that WTX inhibits Wnt signaling by degrading b-catenin (Major et al., 2007) . WTX is likely to have a role during kidney development, as WTX is expressed in an overlapping pattern with WT1 expression during kidney development and modulates WT1 activity acting as a transcriptional cofactor (Rivera et al., 2009) . WTX may have other functions as well. The N-terminus of WTX protein contains two distinct phosphatidylinositol bisphosphate-binding domains, which renders its localization to the plasma membrane (Grohmann et al., 2007) . WTX also interacts with the adenomatous polyposis coli (APC) protein and attracts APC to the plasma membrane. This prevents the association of APC with microtubules, affecting the functional roles of APC in cell adhesion and migration (Grohmann et al., 2007) .
Although HEK293 cells express a detectable level of endogenous WT1, our previous study successfully validated WT1 targets such as MKP3 in HEK293 cells engineered to conditionally overexpress WT1 (Morrison et al., 2008) . To better understand the ability of WTX to alter cell growth, we established cells expressing WTX in the same inducible manner as the WT1 system and profiled gene expression modulated by WTX. We, thus found that Wilms tumor suppressors, WTX and WT1, affect similar pathways and induce cell-cycle arrest through p21.
Results
The EGFP-WTX fusion protein preserved the localization and internal splicing of natural WTX To investigate WTX function, we made a series of WTX deletion constructs as EGFP fusion proteins to monitor protein expression and localization ( Figure 1a ). Deletion constructs WTX358 and WTX565 were designed based on Wilms tumor-associated truncation mutants (Rivera et al., 2009) . WTX overexpression was previously reported to cause profound cell death on transfection. Accordingly all of the EGFP-WTX fusions led to apoptosis of HEK293 cells, except WTX831-1135 (Figure 1c ; Supplementary data 1). This suggests that a region containing amino-acid residues 1-830 is important for the apoptotic function of WTX. As both mutants WTX565 and WTX566-1135 induced cellular death on transfection, there may be at least two independent domains responsible for cellular death. In contrast, transient overexpression of WT1 did not cause death of these cells. Immunoblot analysis showed the presence of two protein species in lysates of cells transfected with WTX-FL, WTX565 and WTX830 consistent with a previously demonstrated internal splicing event that deletes amino acids 51-326 of WTX (Jenkins et al., 2009; Rivera et al., 2009) (Figure 1b ; Supplementary data 2). Although knockdown of WTX was shown to increase b-catenin levels (Major et al., 2007) , overexpression of EGFP-WTX protein did not affect the steady state level of total and active b-catenin in HEK293 and other cell types (Figure 1b ; Supplementary data 2). A previous study mapped WTX interaction with b-catenin to a region between amino acids 368-804 of WTX. This suggests that the ability of WTX to induce apoptosis is not related to its physical interaction to b-catenin. Again consistent with a prior study (Grohmann et al., 2007) , EGFP-WTX-FL was prominent at the plasma membrane, potentially because of the action through two phosphatidylinositol bisphosphatebinding domains (amino acids 2-142 and 143-209) ( Figure 1d ). As WTX566-1135 also induced apoptosis, WTX-mediated apoptosis may be independent of plasma membrane localization as well. Immunofluorescence analysis showed that the cellular localization of EGFP-WTX-FL, EGFP-WTX358 and EGFP-WTX565 was similar, with prominent expression at the plasma membrane and even distribution throughout the cell (Supplementary data 3). WTX831-1135 protein was more evenly distributed throughout the cell with a punctuate nuclear domain, but no prominent plasma membrane localization (Supplementary data 3) . Fluorescence-activated cell sorting (FACS) analysis showed that when compared with parental cells, the inducible EGFP and EGFP-WTX cells expressed some protein at baseline, which increased on doxycycline addition (Figure 2a) . Therefore, we measured WTX mRNA transcripts in the absence and presence of doxycycline (Figure 2b) . Consistent with the FACS analysis data, EGFP-WTX transcripts were readily detected even in the absence of doxycycline only in the presence of reverse transcriptase. In contrast, the endogenous WTX transcript was detected only at a cycle of threshold (C t ) of 29 (data not shown). EGFP-WTX-FL pools separated into two different populations, dim and bright, on doxycycline addition (Figure 2a) . Therefore, we induced the cells for 2 days with doxycycline and sorted the dim (shown as WTX-FL dim) and bright (WTX-FL bright) populations to separately examine their biological properties. The sorted cells were expanded in the absence of doxycycline for 10 days before reinduction of WTX protein. Interestingly, after reinduction, WTX expression in both the dim and bright pools again separated into two populations with mean GFP fluorescence of about 300 and 3000 (Figure 2c ). In contrast, WTX831-1135 pools on doxycycline induction formed a single population with a mean fluorescence of about 30 000 (Figure 2c ). The protein expression in these pools at the baseline was also confirmed by immunoblot analysis (Figure 2d ). In conclusion, although high levels of EGFP and WTX831-1135 expression was well tolerated, high level of WTX-FL expression could not be achieved, consistent with the toxic effect seen in transient overexpression.
Next, we examined the growth rates of different WTX pools and compared with EGFP control cells in the absence and presence of doxycycline. WTX-FL expression in HEK293 cells significantly suppressed growth in both the absence and presence of doxycycline in the dim and bright pools (Figure 3a truncation mutants WTX358 and WTX565 also significantly inhibited cell growth compared with EGFP but in a lesser extent than WTX-FL, whereas WTX831-1135 expression did not show any inhibition (Figure 3b , right panel). Of note, WTX831-1135 is deleted for important known functional domains required for membrane localization, internal splicing and b-catenin interaction. WTX831-1135 protein was highly expressed at the baseline and had no effects on cellular growth even after induction of the protein. This suggests that amino acids 831-1135 of WTX are unlikely to be involved in controlling cell growth. Taken together, WTX inhibited cellular proliferation and there was a continuous selection against high level of WTX expression. This explained the difficulty of establishment of stable clones of these cells.
WTX caused cell-cycle arrest in G 0 /G 1 Cell-cycle analysis was also performed in the absence and presence of doxycycline and compared with EGFP cells. Even at the baseline, WTX expression led to accumulation of cells in G 0 /G 1 from 39% in EGFP cells to 45% in WTX-FL dim cells and to 48% in WTX-FL bright cells (Figure 3b , left panel). When WTX expression was induced in WTX-FL dim and bright cells, G 0 /G 1 accumulation was increased from 42% in EGFP cells to 50 and 53%, respectively. These data is consistent with the WTX effects on cellular growth. On doxycycline addition, WTX565 expression induced cell-cycle arrest (48%) to a similar extent as to WTX-FL, and WTX358 did not cause a statistically significant change ( Figure 3b , right panel). Consistently, WTX831-1135 expression had no effect on the cell cycle. This suggests that the tumor-associated WTX358 and WTX565 mutations retain some of the functions of wild-type WTX and a domain containing amino acids 831-1135 is not involved in controlling cell cycle. In summary, WTX expression induced cell-cycle arrest in G 0 /G 1 phase, like WT1 (Englert et al., 1997) .
Gene expression profiling supported the role of WTX in growth inhibition and cell-cycle arrest Although WT1 is a transcription factor containing four zinc finger domains, WTX does not contain any known conserved functional protein domains. Previously, WTX was shown to stimulate WT1-mediated activation of Amphiregulin (Rivera et al., 2009) . To gain insight into the growth suppressive properties of WTX, we compared alterations in gene expression modulated by WTX-FL, WTX358, WTX565 and WTX831-1135 with gene expression in HEK293-EGFP cells in the presence of doxycycline, when WTX expression and biological activity in the cell cycle was maximum. EGFP and WTX expression after doxycycline addition were confirmed by FACS analysis before collecting the cells (Figure 2a ). For WTX358, we used sorted pools (Figure 2c -6) as half of the cells were not GFP positive (Figure 2a) . In a biological triplicate experiment, WTX-FL and WTX565 affected the expression of 494 (450 genes) and 450 (417 genes) probe sets, whereas WTX358 and WTX831-1135 affected the expression of 4 (2 genes) and 46 (41 genes) probe sets, respectively (corrected Po0.005 and Xtwofold change) (Figure 4a ; Supplementary data 4, 5, 6, and 7). Of the two genes affected by WTX358, TSC22D3 was differentially regulated by all four WTX constructs, whereas SPANXN3 was regulated by WTX-FL, WTX358 and WTX565 only. Most notably, WTX565 shared a significant number of common genes (242 probe sets) with WTX-FL, whereas WTX358 and WTX831-1135 shared a small set of genes. This is consistent with the result that WTX565 induced cell growth inhibition and cell-cycle arrest to a similar extent as to WTX-FL, but WTX358 and WTX831-1135 had little or no effect.
Given that both WTX and WT1 can induce cell-cycle arrest, we compared the gene expression profiles between WTX-FL and WT1. A total of 405 probe sets (378 genes) (Supplementary data 8) were affected by WT1 and WTX-FL and WT1 shared 147 probe sets (131 genes) in common (Figure 4b ). To identify which pathways were enriched among the target genes of WTX-FL, WTX565 and WT1, we performed pathway analysis using Ingenuity (Ingenuity System, Redwood City, CA, USA). WTX565 influenced the same top 10 biological functional pathways enriched in WTX-FL (Figure 4c ). Interestingly, WTX and WT1 converged on many similar pathways implicated in the cellular growth, cell-to-cell signaling, tissue development, cancer, cell cycle, cell death and cardiovascular system development at a statistically significant level (Figure 4c ). This result was consistent with the biological observation that both WT1 and WTX slowed growth and caused cell-cycle arrest (Supplementary data 9). Notably, more genes (34) were affected by WTX than by WT1 (6 genes) in the cell-cycle network. Among genes regulated by WTX in the cells, WTX regulated genes, including BAD, CDKN1A, CD44, COPS2, ELAVL1, MYC, NRG1, PLAC1, SKP2, SSTR2 and TYMS, whereas WT1 regulated genes, including CD44, DDIT3, PRKCH and CDKN2A. Taken together, these data suggest that WT1 and WTX may affect similar functional gene networks, while regulating, for most of the part, the separate sets of genes.
WTX activates p21 in a p53-independent manner As WT1 caused cell-cycle arrest in G 0 /G 1 through activation of p21 (Englert et al., 1997) , we specifically examined CDKN1A (p21) levels in response to WTX. CDKN1A mRNA was upregulated at the baseline in WTX-FL and WTX565 cells compared with EGFP cells and further increased on doxycycline addition, whereas WTX358 and WTX831-1135 did not affect CDKN1A mRNA levels (Figure 5a ). This was consistent with the Illumina expression array data (Supplementary data 11) . Accordingly, p21 protein was prominently upregulated on induction of WTX-FL and WTX565 (Figure 5b) . p21 upregulation by WT1 in HEK293-5.1 was used as comparison (Morrison et al., 2008) . To further prove that WTX affects p21 promoter activity, we cotransfected a p21 promoter reporter plasmid with wild-type WTX and deletion mutant constructs. Consistent with the cell-cycle analysis (Figure 3b ), the p21 promoter was responsive to WTX-FL and WTX565 and not to WTX358 and WTX831-1135 in HEK293 cells (Figure 5c ). p21 transcription is induced by p53, yet WT1 activates p21 independently of p53 (Englert et al., 1997) . WTX induction of p21 was also p53 independent as WTX-FL activated a p21 reporter in p53 null HCT 116 cells (Figure 5d ). Curiously, WTX358 did Figure 2 Inducible expression of EGFP-WTX constructs in HEK293 cells (a). Stable expression of the WTX was measured by flow cytometry in the absence and presence of doxycycline for 3 days. An arbitrary gate setting at 0.3% GFP positive from HEK293 cells was applied to quantify the fraction of GFP-positive cells. (b) Total RNA was isolated at day3 after induction and treated with DNAse before reverse transcription. The end point PCR product using indicated primer sets after 30 cycles was loaded on the gel to visualize amplicons. The real-time amplification plot is shown and C t numbers of WTX and GAPDH are indicated. (c) Sorted cells were analyzed by FACS in the absence and presence of 2 mg/ml doxycycline after 3 days reinduction. (d) WTX protein expression was measured by immunoblotting using anti-GFP. GAPDH was used as a loading control. A total of 100 mg of total lysate was loaded per lane. WTX induces cell-cycle arrest through p21 MK-H Kim et al not activate p21 transcription and a p21 reporter but induced p21 protein in HEK293 cells. However, WTX358 activated a p21 reporter in the HCT116-p53 null cells. Taken together, these data suggest that the WTX truncation mutants are on a spectrum, retaining some functions of full-length WTX. As WTX shuttles to the nucleus and is recruited to the promoter of a WT1 target, Amphiregulin, enhancing the transcriptional activity of WT1 (Rivera et al., 2009 ), we performed chromatin immunoprecipitation (ChIP) with real time PCR quantification to determine whether WTX was directly recruited to the p21 promoter. There was significantly more p21 chromatin captured with GFP antibody in cells expressing the GFP-WTX protein when compared with parental HEK293 cells (Figure 5e , left middle). However, the GFP antibody did not significantly enrich for the promoter of the NUTF2 gene, which is not regulated by WTX (Figure 5e, right) . Therefore, WTX was bound to the p21 promoter in EGFP-WTX inducible cells in vivo. Taken together, these data indicate that WTX activates p21 transcription through recruitment to the promoter.
Discussion
WTX is somatically mutated and deleted in a subset of Wilms tumors, however it remains to be determined whether WTX mutation is a major driver of Wilms tumorigenesis or simply contributes to progression at later stages of development. The importance of WTX mutation in tumor development may be related to the nature of the mutation. Along these lines, germline nonsense or frame-shift mutations of the WTX gene, presumably leading to the production of very shorttruncated proteins are associated with fetal lethality in males, whereas slightly longer truncations ending at amino acid 425 or 502, such as Y425X, were associated with survival and developmental anomalies (Jenkins et al., 2009 ). Hence, it is possible that tumors with very short truncation mutations of WTX may be distinct from those with longer forms of WTX proteins. In accordance with this idea, we found that WTX358 was a near complete loss-of-function mutant of WTX with limited ability to cause cell death, p21 induction or alteration in gene expression in HEK293 cells, whereas in this system WTX565 was a hypomorphic form of WTX.
Biochemical studies demonstrate that WTX inhibits Wnt signaling by direct physical interaction with the b-catenin destructive complex. Transient reporter assays show that the activity of a TCF/b-catenin responsive reporter gene increases on WTX knockdown by small interfering RNA (Major et al., 2007) . In contrast, our results as well as those of Major et al. indicate that overexpression of WTX does not affect b-catenin levels. WTX may be in a stochiometric relationship with other members of the b-catenin destruction complex and loss of its expression may hinder the complex, whereas overexpression does not lead to further assembly of such complexes. Nevertheless, as increased Wnt signaling is associated with increased skeletal ossification as seen in congenital WTX mutation, the available evidence does suggest that WTX is a negative regulator of canonical Wnt signaling (Bennett et al., 2005; Morvan et al., 2006; Jenkins et al., 2009) . However, our results indicate that the ability of overexpressed WTX to slow cell growth and induce cell death is not associated with changes in b-catenin levels.
WTX mutations exist in tumors with and without b-catenin mutations (Ruteshouser et al., 2008) , whereas b-cartenin mutations are found almost exclusively in the presence of loss-of-function mutations of WT1 (Maiti et al., 2000) . We previously showed that WT1 inhibited the transcriptional function of both wild-type and constitutively active, gain of function b-catenin alleles . These data suggest that b-catenin mutations are only found in WT1 mutant tumors because the loss of WT1 allows the full transcriptional and growth promoting properties of mutant b-catenin to be expressed. In contrast, the coincidence of WTX and b-catenin mutations suggests that although WTX may have a negative role in the Wnt pathway, WTX loss is not rate limiting for the action of b-catenin mutations. Recent studies suggest that WTX is mutated in only a fraction of the cells within a Wilms tumor and may represent a progression factor rather than an initial driver of tumorigenesis. Furthermore, WTX mutations are not associated with differences in the clinical presentation or outcome of Wilms tumors (Wegert et al., 2009) . Microarray experiments show distinct differences in the gene expression profile of WT1 wild-type and mutant tumors, with many of the changes in the WT1 mutant tumors due, in part, to activation of the Wnt pathway (Li et al., 2004) . Gene expression profiles of WT1-replete, CTNNB1 wild-type Wilms tumors with or without WTX mutations, may clarify the role of WTX in Wilms tumorigenesis.
The expression patterns of WT1 and WTX during mouse kidney development are similar with dramatic decreases 1 week after birth (Rivera et al., 2007) . Therefore, WTX may function in concert with WT1, possibly as a cofactor during kidney development (Rivera et al., 2009) . The Wnt pathway is essential for normal kidney development and enforced expression of activated b-catenin leads to hyperproliferation of the putative metanephric mesenchyme leading to overgrowths that resemble the blastemal elements of Wilms tumor (Park et al., 2007; Schmidt-Ott et al., 2007) . WT1 and WTX may both act to limit the extent of Wnt signaling as the metanephric mesenchyme condenses into mature epithelial structures. Gene expression profiling showed that the WTX and WT1 tumor suppressors acted on similar genetic pathways involved in growth, cancer, development and cardiovascular system. It is also notable that a patient carrying a premature termination mutant of WTX (Y425Ter) displays cardiac anomalies and WT1 is required for heart development (Kreidberg et al., 1993; Jenkins et al., 2009) . Like WT1, WTX was recruited to the p21 promoter and could stimulate p21 transcription in a p53-independent manner. Although WT1 directly binds to the p21 promoter through its zinc finger domain to activate p21, WTX has no evident DNA binding domain and is likely bound to the p21 promoter through protein-protein interactions. During kidney development, WTX may stimulate p21 through interaction with WT1 itself or, as evidenced by its ability to stimulate p21 in colon cancer cells and HEK293 cells that express little WT1, through other transcriptional regulators. Whether WTX acts in vivo to inhibit tumor growth by cell-cycle regulation or modulation of apoptosis remains to be determined.
Our study demonstrates that WTX shares properties with the WT1 tumor suppressor such as the abilities:
(1) to induce cell-cycle arrest through binding to the p21 promoter and (2) to induce programmed cell death. WT1 and WTX influence similar pathways in HEK293 cells, for the some part, through distinct sets of genes. The ability of WTX to regulate genes appears to be, in part, due to its ability to bind to promoters such as p21, most likely through protein-protein interactions. The loss of function of WTX deletion mutants correlated with loss of the ability to influence gene expression. Further studies of the mode of gene regulation by WTX, and tumor and malformation À/À cells) in triplicates. After 16 h, cells were lyzed with 100 ml 1X lysis buffer and 20 ml lysates were used for luciferase assay. Transfection efficiency was monitored by GFP signal. The data represents three independent experiments. (e) HEK293 and GFP-WTX-FL cells were incubated with doxycycline for 2-3 days, processed for ChIP and quantified by real-time PCR. Enrichment of precipitated chromatin is shown as the percent input chromatin recovered. PCR of nonspecific promoter (NUTF2 promoter) region was included to check specificity and IgG ChIP was used to monitor background signal. associated mutants should lead into greater insights into normal and malignant development.
Materials and methods

Plasmids
The human wild-type WTX cDNA was amplified from Wilms tumor cell line CCG99-11 using the StrataScript One-Tube RT-PCR System (Agilent Technologies, Santa Clara, CA, USA). The WTX full-length cDNA and deletion constructs were cloned into pEGFP-C1 (BD Biosciences, San Jose, CA, USA) using EcoRI and BamHI sites to make in-frame EGFP fusion proteins. For inducible expression constructs, each EGFP-WTX fusion construct or EGFP was excised from pEGFP-C1 and cloned into pBIG2i (Strathdee et al., 1999) using NheI and BamHI sites.
Cell culture and transfection methods HEK293 cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 10 mM penicillinstreptomycin. Cells were transfected using FuGENE 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA). All pBIG2i-EGFP-WTX constructs were transfected into HEK293 cells and stable pools were selected with 100 mg/ml of hygromycin (Invitrogen, Carlsbad, CA, USA) for 10 days. WTX stable pools were maintained in complete Dulbecco's modified Eagle's medium containing 50 mg/ml of hygromycin.
Quantitative PCR Total RNA (1 mg) was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) in a 20 ml reaction volume. A total of 2 ml of five times diluted cDNA was used in a 25 ml reaction volume by QuantiTect SYGR synthesis kit (Qiagen, Valencia, CA, USA) to quantify mRNA level. Primers used in this study are following. 
Immunoblot analysis
Polyclonal WTX antibody directed against WTX sequence CARAREAHAREAHA was produced in rabbit and affinitypurified from sera (Covance, Princeton, CA, USA). For immunoblot analysis the anti-WTX antibody was used at a concentration of 0.94 mg/ml. The following primary antibodies were used in this study: mouse anti-GFP monoclonal (1/1000, Millipore, Billerica, MA, USA); anti-active-b-catenin mouse monoclonal (anti-ABC, clone 8E7, 1/1000, Millipore); anti-p21 (DCS60) (1:1000, Cell Signaling, Danvers, MA, USA); and anti-GAPDH mouse monoclonal (1/20 000, Millipore). For the detection, one of the following conjugated antisera was used (GE Healthcare, Piscataway, NJ, USA): peroxidase-donkey anti-rabbit IgG (1/5000); peroxidase-sheep anti-mouse IgG (1/5000). The proteins were visualized using ECL (GE Healthcare).
Cell proliferation assays and cell-cycle analysis Cells were seeded at 5 Â 10 5 cells per 10 cm plate in the absence and presence of 2 mg/ml of doxycycline and the total cell number was counted 3 to 4 times for each condition by Countess (Invitrogen). Cell-cycle analysis was performed on day 2 after doxycycline addition using a BrdU Flow Kit (BD Biosciences), pulsing cells for 30 min with bromodeoxyuridine. Total cell DNA as measured by 7-amino-actinomycin D staining and bromodeoxyuridine reactivity was analyzed by flow cytometry on a BD LSR II.
Microarray expression profiling
Total RNA from each plate of triplicate cultures of HEK293-EGFP, WTX-FL, WTX358, WTX565 and WTX831-1135 cells was isolated using the RNeasy Mini Kit (Qiagen) 3 days after the addition of doxycycline (2 mg/ml). Expression array profiling was performed using the Illumina Human-6_v3 Expression BeadChip (Genomics Core facility, Cleveland Clinic, OH, USA). Normalized and background subtracted expression values were analyzed using GeneSpringGX 10.0.2 software (Agilent Technologies). For each expression comparison, HEK293-EGFP treated with doxycycline served as the baseline. The probe sets were filtered out when raw intensity values below 100 were observed in five out of six samples. Significance analysis was performed by unpaired t-test and Benjamini-Hochberg multiple testing correction, and differentially expressed genes were selected using a twofold cutoff with corrected Po0.005 for the biological triplicate samples. Pathway analysis was done using Ingenuity pathway analysis (Ingenuity System).
Luciferase assays HEK293 and HCT116 p53À/À cells were transfected using Fugene 6 (Roche) and Lipofectamine LTX Plus (Invitrogen) reagents, respectively, according to manufacturer's protocol. A total of 70 ng of p21-promoter reporter (a generous gift from Dr Harris Perlman, Northwestern University) was co-transfected with 420 ng of either empty vector (pEGFP-c1) or different EGFP-WTX constructs into 3 Â 10 5 cells in 24-well plates in triplicates. Transfection efficiency was monitored by a GFP signal. Luciferase activity was measured at 16 h posttransfection using Luciferase assay kit (Promega, Madison, WI, USA) and s.d.'s were derived from triplicates.
ChIP assay
ChIP was performed as previously described . HEK293 cells and GFP-WTX-FL stable pools were induced with doxycycline for 2-3 days before cross-linking. In total, 10 million cells were used per ChIP and 5 mg of antibody was added for each ChIP. Input and ChIP samples were purified using the Qiagen PCR purification kit. Quantitative PCR was performed using Stratagene M Â 3000 machine in a 25 ml reaction volume . Antibodies for ChIP include normal rabbit IgG (Millipore) and rabbit polyclonal GFP antibody (ab290, Abcam, Cambridge, MA, USA). Primers used are follows; p21-Forward: 5 0 -GCTGCCGAAGTCAGTTC CTTGTG-3 0 , p21-Reverse: 5 0 -ACCTGCCGCAGAAACACCTG TG-3 0 , as a negative control; NUTF2-Forward: 5 0 -GAGACTGG CCTTACCACAAATGT-3 0 , NUTF2-Reverse:5 0 -TCAAACTTCT ACAGTCAGGGGTCC-3 0 .
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